IDO1 Inhibitor RY103 Suppresses Trp-GCN2-Mediated Angiogenesis and Counters Immunosuppression in Glioblastoma

IDO1 Inhibitor RY103 Suppresses Trp-GCN2-Mediated Angiogenesis and Counters Immunosuppression in Glioblastoma

Glioma is characterized by strong immunosuppression and excessive angiogenesis. Based on existing reports, it can be speculated that the resistance to anti-angiogenic drug vascular endothelial growth factor A (VEGFA) antibody correlates to the induction of novel immune checkpoint indoleamine 2,3-dio...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron: Zikang Xing, Xuewen Li, Zhen Ning Tony He, Xin Fang, Heng Liang, Chunxiang Kuang, Aiying Li, Qing Yang
Fformat: Erthygl
Iaith:English
Cyhoeddwyd: MDPI AG 2024-06-01
Cyfres:Pharmaceutics
Pynciau:
glioma
angiogenesis
indoleamine 2,3-dioxygenase 1
tryptophan depletion
general control nonderepressible 2
Mynediad Ar-lein:https://www.mdpi.com/1999-4923/16/7/870

Rhyngrwyd

https://www.mdpi.com/1999-4923/16/7/870

Eitemau Tebyg